


RESEARCH

Open Access



Knockout of secretin ameliorates biliary and liver phenotypes during alcohol-induced hepatotoxicity

Konstantina Kyritsi^{1†}, Nan Wu^{1†}, Tianhao Zhou^{1†}, Guido Carpino², Leonardo Baiocchi³, Lindsey Kennedy^{1,4}, Lixian Chen¹, Ludovica Ceci^{1,2}, Alison Ann Meyer¹, Nipuni Barupala¹, Antonio Franchitto⁵, Paolo Onori², Burcin Ekser⁶, Eugenio Gaudio², Chaodong Wu⁷, Corinn Marakovits¹, Sanjukta Chakraborty⁸, Heather Francis^{1,4*}, Shannon Glaser^{8*} and Gianfranco Alpini^{1,4*} 

Abstract

Background Alcohol-related liver disease (ALD) is characterized by ductular reaction (DR), liver inflammation, steatosis, fibrosis, and cirrhosis. The secretin (Sct)/secretin receptor (SR) axis (expressed only by cholangiocytes) regulates liver phenotypes in cholestasis. We evaluated the role of Sct signaling on ALD phenotypes.

Methods We used male wild-type and Sct^{-/-} mice fed a control diet (CD) or ethanol (EtOH) for 8 wk. Changes in liver phenotypes were measured in mice, female/male healthy controls, and patients with alcoholic cirrhosis. Since Cyp4a10 and Cyp4a11/22 regulate EtOH liver metabolism, we measured their expression in mouse/human liver. We evaluated: (i) the immunoreactivity of the lipogenesis enzyme elongation of very-long-chain fatty acids 1 (Elovl, mainly expressed by hepatocytes) in mouse/human liver sections by immunostaining; (ii) the expression of miR-125b (that is downregulated in cholestasis by Sct) in mouse liver by qPCR; and (iii) total bile acid (BA) levels in mouse liver by enzymatic assay, and the mRNA expression of genes regulating BA synthesis (cholesterol 7 α -hydroxylase, Cyp27a1, 12 α -hydroxylase, Cyp8b1, and oxysterol 7 α -hydroxylase, Cyp7b1) and transport (bile salt export pump, Bsep, Na⁺-taurocholate cotransporting polypeptide, NTCP, and the organic solute transporter alpha (OSTa) in mouse liver by qPCR.

Results In EtOH-fed WT mice there was increased biliary and liver damage compared to control mice, but decreased miR-125b expression, phenotypes that were blunted in EtOH-fed Sct^{-/-} mice. The expression of Cyp4a10 increased in cholangiocytes and hepatocytes from EtOH-fed WT compared to control mice but decreased in EtOH-fed Sct^{-/-} mice. There was increased immunoreactivity of Cyp4a11/22 in patients with alcoholic cirrhosis compared to controls. The expression of miR-125b decreased in EtOH-fed WT mice but returned at normal values in EtOH-fed Sct^{-/-} mice. Elovl1 immunoreactivity increased in patients with alcoholic cirrhosis compared to controls. There was no difference

[†]Konstantina Kyritsi, Nan Wu and Tianhao Zhou shares the first authorship

*Correspondence:

Heather Francis

heafranc@iu.edu

Shannon Glaser

sglaser@tamu.edu

Gianfranco Alpini

galpini@iu.edu

Full list of author information is available at the end of the article



This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

in BA levels between WT mice fed CD or EtOH; BA levels decreased in EtOH-fed *Sct*^{-/-} compared to EtOH-fed WT mice. There was increased expression of *Cyp27a1*, *Cyp8b1*, *Cyp7b1*, *Bsep*, *NTCP* and *Osta* in total liver from EtOH-fed WT compared to control mice, which decreased in EtOH-fed *Sct*^{-/-} compared to EtOH-fed WT mice.

Conclusions Targeting *Sct*/*SR* signaling may be important for modulating ALD phenotypes.

Keywords Biliary senescence, Ductular reaction, Fatty liver diseases, Hepatic steatosis, Lipogenesis

Introduction

Alcohol-related liver diseases (ALD) account for nearly 50% of liver-related deaths in the US, which are attributed to excessive drinking habits [1]. The molecular mechanisms regulating the pathogenesis of ALD are complex and include oxidative stress, lipotoxicity, mitochondrial dysfunction, and possible derangement of the gut-liver axis [2]. Hepatic steatosis and fibrosis are hallmarks of ALD [3, 4], and extensive ductular reaction (DR) is also observed, but the beneficial or detrimental roles of DR in the progression of ALD remain undefined [5–8]. For example, the expansion of liver progenitor cells (associated with ALD-induced DR) correlates positively with the severity of liver disease and short-term mortality in patients with alcohol-induced hepatitis (AH) [7]. Supporting a beneficial role for DR in the modulation of liver phenotypes, a study demonstrated that neo-ductular progenitor cells regenerate hepatocytes damaged by ethanol (EtOH) [5]. Although DR is observed in several mouse models of liver damage, such as primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and extrahepatic cholestasis, there is not a well-defined consensus on whether DR has a beneficial or detrimental role in ALD [8–10].

The mechanisms leading to deranged bile secretion (i.e., cholestasis) and compensatory DR during ALD are undefined. Changes in bile duct permeability, compression of small biliary branches, microtubule disassembly, and impaired hepatocyte bile acid (BA) extrusion are potential alterations that might explain ALD-related cholestasis [11]. Several gastrointestinal hormones, neuropeptides, and other biological molecules modulate biliary functions [8, 12–15]. Most important among these factors is secretin (*Sct*), which is only expressed/secreted by cholangiocytes in the liver [12] and is considered a principal regulator of biliary secretion, senescence, and DR [16–19]. The effects of *Sct* are mediated by interaction with basolateral secretin receptor (*SR*, expressed only by cholangiocytes in the liver) [20], which leads to increased intracellular adenosine 3',5'-cyclic monophosphate (cAMP) levels, protein kinase A phosphorylation, and opening of cystic fibrosis transmembrane

conductance regulator (CFTR) enhancing HCO_3^- secretion through activation of anion exchanger 2 (AE2) [21–24].

There is growing information regarding the changes in the levels of *Sct* and the expression of the *Sct*/*SR*/*miRNA-125b* axis regulating biliary senescence, DR, and hepatobiliary injury [9, 16]. For example, in pathological states associated with enhanced biliary damage/DR there is enhanced expression of *Sct*/*SR* signaling and *Sct*-induced bicarbonate-rich choleresis [16]. In contrast, during damage/loss of bile ducts there is reduced *SR* signaling and *Sct*-stimulated bile secretion [16]. Furthermore, increased *Sct* signaling triggers biliary senescence/DR, and liver fibrosis by autocrine/paracrine pathways through upregulation of transforming growth factor β 1 (*TGF β 1*) signaling [9]. In mouse models of extrahepatic obstruction by bile duct ligation (BDL) and PSC (multidrug resistance 2 knockout mice, *Mdr2*^{-/-}), there is a marked increase in DR accompanied by enhanced biliary senescence and *TGF β 1* expression that activate hepatic stellate cells (HSCs) by paracrine pathways [9, 10]. Similarly, in an early-stage PBC mouse model and human samples, there are increased levels of *Sct* in serum and bile and upregulation of *Sct*/*SR* signaling. In contrast, late-stage PBC models and human samples are characterized by ductopenia [25] accompanied by loss of AE2 and reduced ductal HCO_3^- secretion (i.e., defective bicarbonate “umbrella”) as well as reduced *Sct* levels and *Sct* signaling [13, 15, 25–28]. Several studies have shown that inhibition of *Sct*-dependent signaling in BDL and *Mdr2*^{-/-} mice (by genetic knockout or pharmacological inhibition of *SR*) reduces biliary damage/DR and liver fibrosis by inhibiting *TGF β 1* signaling [9, 17]. Furthermore, inhibition of biliary *Sct*/*SR* signaling (associated with reduced DR) inhibits hepatic steatosis by downregulation of the lipid biosynthesis gene elongation of very-long-chain-fatty acids (*Elovl1*) through increased biliary *miRNA-125b* coupled with decreased angiogenesis [29]. These findings demonstrate that a proper balance in *Sct* levels and *Sct*-dependent signaling is critical to maintaining biliary homeostasis, since upregulation of *Sct*-dependent signaling triggers DR/biliary senescence. In contrast, *Sct*/*SR* axis reduction likely induces biliary loss/ductopenia [9, 13, 16, 17, 30]. With this background and, since alcohol-related impairment of bile secretion is

undefined, we aimed to assess the role of the Sct/SR/miR-125b signaling axis in a murine model of ALD-induced cholestasis and human samples from healthy control livers and patients with alcoholic cirrhosis.

Materials and methods

Materials

Unless otherwise indicated, reagents were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). Cell culture reagents and media were obtained from Invitrogen Corporation (Carlsbad, CA). Commercially available ELISA kits to measure Sct levels in mouse and human serum samples were purchased from Phoenix Pharmaceuticals (Burlingame, CA). Total RNA was extracted using the mirVana miRNA Isolation Kit from ThermoFisher Scientific (Waltham, MA). The iScript cDNA Synthesis Kit and iTaq Universal SYBR Green Supermix were purchased from Bio-Rad (Hercules, CA). All mouse and human primer information for quantitative polymerase chain reaction (*q*PCR) is listed in Additional file 3: Table S1. The list of the mouse and human antibodies used is shown in Additional file 4: Table S2.

Animal models

Animal procedures were performed following protocols approved by the Indiana University School of Medicine Institutional Animal Care and Use Committees. C57BL/6 J wild-type (WT) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). The Sct^{-/-} mouse colony (on a C57BL/6 background) [31] is established in our facility. Male WT and Sct^{-/-} mice (at 14 wk of age) were fed a Lieber-DeCarli EtOH liquid diet (5% vol/vol EtOH) for 8 wk and gavaged once per wk with 31.5% vol/vol EtOH (5 gm/kg body weight, BW) or 45% wt/vol maltose dextrin, for isocaloric equivalence, throughout the 8 wk feeding period [32]. All mice were subjected to acclimatization beginning with a 1% EtOH diet and increasing 1% each day until reaching 5% vol/vol EtOH. Six hours before sacrifice and serum, liver samples, cholangiocyte and hepatocyte collection, the mice were given a single gavage in the morning with 31.5%

vol/vol EtOH or 45% wt/vol maltose dextrin as described above. All mice were housed in a temperature-controlled environment (22 °C) with 12:12-h light–dark cycles. In all groups, body weight (BW), liver weight (LW) and LW to BW ratio (an index of liver growth) [23] were measured (Table 1). The EtOH and control groups were given supplemental nesting materials as suggested by the Indiana University School of Medicine Laboratory Animal Resource Center veterinary staff to assist in body heat retention and reduce the possibility of EtOH-induced hypothermia and/or increased mortality.

Human samples

Human samples from healthy control livers (n=9) were purchased from Sekisui XenoTech (Kansas City, KS). Additionally, liver samples from healthy controls (n=5) and patients with alcoholic cirrhosis (n=19), as well as serum samples from healthy controls (n=6) and patients with alcoholic cirrhosis (n=50), and bile from healthy controls (n=9) and patients with alcoholic cirrhosis (n=9), were obtained from Dr. Burcin Ekser (co-author in the study) under a protocol approved by the Institutional Review Board (IRB) at Indiana University School of Medicine. The demographic characteristics of the human samples are listed in Additional file 5: Table S3 and Additional file 6: Table S4. In the Figures we use term control(s) to indicate human healthy control livers.

Measurement of Sct/SR/CFTR/AE2 Immunoreactivity/Expression in Liver Sections, Sct Mouse and Human Serum Levels, and Bicarbonate Bile Levels in Healthy Controls and Patients with Alcoholic Cirrhosis

We evaluated the biliary immunoreactivity of: (i) Sct, SR and CFTR by immunohistochemistry in mouse liver sections (5 μm thick); and (ii) Sct, by immunohistochemistry, and SR, CFTR and AE2 by immunohistochemistry and/or immunofluorescence in liver sections (paraffin-embedded, 5 μm thick) or (frozen, 4 μm thick, co-stained with the biliary marker, CK19) [17] from healthy controls and patients with alcoholic cirrhosis. Following immunohistochemistry, sections

Table 1 Measurement of liver and body weight, liver to body weight (LW/BW) ratio, liver steatosis, inflammation and total liver bile acid (BA) levels

Treatment (mice)	Liver weight, g	Body weight, g	LW/BW ratio, %	Steatosis, %	Inflammation, %	TBA, mM
WT CD	1.30 ± 0.08 (n=6)	29.86 ± 1.15 (n=6)	4.33 ± 0.16 (n=6)	0.8 ± 0.84 (n=6)	0.60 ± 0.89 (n=6)	18.54 ± 3.19 (n=9)
Sct ^{-/-} CD	1.77 ± 0.20 (n=4)	38.34 ± 2.30 (n=4)	4.57 ± 0.30 (n=4)	1.33 ± 0.58 (n=4)	1.00 ± 0.00 (n=4)	16.23 ± 2.62 (n=7)
WT EtOH	2.17 ± 0.21 ^a (n=4)	30.68 ± 1.73 (n=4)	7.03 ± 0.33 ^a (n=4)	2.60 ± 0.55 ^a (n=5)	1.80 ± 0.45 ^a (n=5)	32.84 ± 7.02 (n=10)
Sct ^{-/-} EtOH	1.24 ± 0.13 ^b (n=5)	29.37 ± 1.58 (n=5)	4.19 ± 0.25 ^b (n=5)	1.25 ± 0.50 ^b (n=3)	1.00 ± 0.00 ^b (n=3)	15.01 ± 3.08 ^b (n=9)

^a *p* < 0.05 vs WT CD

^b *p* < 0.05 vs WT EtOH

were evaluated with an Olympus BX-51 light microscope and imaged by a DP27 Microscope Digital Camera from Olympus (Tokyo, Japan); observations were quantified with Image-Pro 10 software (Media Cybernetics, Inc. Rockville, MD) in a coded fashion. Following immunofluorescent staining, sections were mounted with coverslips using antifade gold-containing 4',6-diamidino-2-phenylindole (DAPI, counterstain, Molecular Probes, Eugene, OR). Images were obtained using a Leica TCS SP8 laser scanning confocal microscope (Leica Microsystems Inc., Buffalo Grove, IL).

To support the immunohistochemical data in liver sections, we measured the: (i) mRNA expression of Sct and SR in isolated mouse cholangiocytes by *qPCR*; and (ii) protein expression of SR in protein (10 mg) in total liver lysate from human healthy controls and patients with alcoholic cirrhosis by Western blotting. We used glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as housekeeping for *qPCR* analysis and loading controls for Western blotting. Protein bands were detected by enhanced chemiluminescence (ECL) using a Pierce ECL Western blot substrate (Thermo Fisher Scientific) and visualized by the BioRad Chemi-Doc Imaging System (BioRad Laboratories, Hercules, CA) and analyzed by Image J (normalized by GAPDH).

The ELISA kits to measure the levels of Sct in human (EK-067-03) and mouse (EK-067-04) serum were purchased from Phoenix Pharmaceuticals, Inc. (Burlingame, CA). Bicarbonate levels in bile from healthy controls and patients with alcoholic cirrhosis were analyzed using the Radiometer ABL90 FLEX plus blood gas analyzer (Radiometer America Inc.; Brea, CA). We measured bicarbonate levels in bile from healthy controls and patients with alcoholic cirrhosis since biliary bicarbonate secretion: (i) depends on and is closely associated with changes in intrahepatic biliary mass (DR) and activation of the Sct/SR signaling axis [13, 22–24]; and (ii) decreases in conditions associated with reduced DR and ductopenic states such as late-stage PBC [15, 21, 26, 30].

Measurement of liver histology, fibrosis and steatosis

Paraffin-embedded liver sections (4 μm thick) were processed for routine histology staining by hematoxylin and eosin (H&E) and Sirius Red/Fast Green. The degree of steatosis (0 = <5%, 1 = 5–33%, 2 = 34–66%, and 3 = >66%) and lobular inflammation (0 = <0.5 foci per field at 20x; 1 = 0.5–1.0; 2 = 1.0–2.0 foci; 3 = >2.0 foci) were assessed by a semiquantitative scoring system [33]; observations were processed in a blinded fashion (see Table 1 and Additional file 1: Fig. S1).

Collagen deposition was evaluated in paraffin-embedded liver sections (4 μm thick) stained with Sirius Red/Fast Green [9]; stained slides were scanned by a digital scanner (Aperio Scanscope CS System, Aperio Digital Pathology, Leica Biosystems) and processed by QuPath (a bioimage analysis software) [34, 35]. Fibrosis extent was calculated on the entire liver section by an algorithm and expressed as the area occupied by Sirius Red-positive fibers with respect to the total areas. Immunofluorescence for desmin (a marker of HSCs) was performed in frozen liver sections (4 μm thick) co-stained with cytokeratin 19 (CK19) [18]. Immunofluorescence was visualized using the SP8 confocal microscope platform (Leica Microsystems Inc.).

Measurement of DR, cholangiocyte and hepatocyte senescence and phenotypic switch of cholangiocytes and hepatocytes

DR was evaluated in paraffin-embedded liver sections (5 μm thick) by immunohistochemistry for CK19 [12]. Stained slides were scanned by a digital scanner (Aperio Scanscope CS System, Aperio Digital Pathology, Leica Biosystems, Milan, Italy) and processed by ImageScope. DR was calculated on the entire section by an image analysis algorithm (ImageScope) and expressed as the area occupied by CK19-positive bile ducts/total area [36].

Hepatic senescence was evaluated in frozen mouse and human liver sections (10 μm thick) by staining for senescence-associated- β -galactosidase (SA- β -gal) using the cellular senescence assay kit (Millipore-Sigma, Billerica, MA); following staining sections were scanned by a digital scanner (Aperio Scanscope CS System, Aperio Digital Pathology, Leica Biosystems) and processed by ImageScope. A semi-quantitative scoring system was applied for quantification of SA- β -gal positive cholangiocytes (0 = <5%; 1 = 6–10%; 2 = 11–30%; 3 = 30–50%; 4 = >50%) [14, 18] in mouse and human samples. We confirmed cholangiocyte and hepatocyte senescence by immunofluorescence for cyclin-dependent kinase inhibitor 2A (p16), co-stained with CK19 or the hepatocyte marker, HNF4 α [29] in frozen liver sections (4 μm thick). We measured the mRNA expression of the senescence gene cyclin-dependent kinase inhibitor 2C (p18) in human total liver samples by *qPCR*.

To determine if hepatocytes (damaged by EtOH feeding) acquire biliary markers, we performed immunofluorescence for CFTR and AE2 in frozen human liver sections (4 μm thick, co-stained with HNF4 α) from healthy controls and patients with alcoholic

cirrhosis. To determine if cholangiocytes differentiate into hepatocytes or acquire hepatocyte markers, we performed immunofluorescence for the hepatocyte bile salt export pump (BSEP) [37] in frozen mouse (WT fed CD or EtOH groups) and human liver sections (4 μm thick, co-stained with CK19) from healthy controls and patients with alcoholic cirrhosis.

Measurement of liver inflammation and neutrophil infiltration

In paraffin-embedded mouse and/or human liver sections (4 μm thick), we evaluated hepatic inflammation by immunohistochemistry for F4/80 (marker of macrophages) [38] and cluster of differentiation 68 (CD68, a protein highly expressed by circulating macrophages) [39]; 5 different fields were analyzed for each group. Slides were scanned with a digital scanner (Aperio Scanscope CS System; Aperio Digital Pathology, Leica Biosystems) and processed with the QuPath software [35]. The number of positive macrophages was automatically quantified by an algorithm and expressed as the area fraction occupied by positive cells (%) with respect to the total parenchymal area.

The mRNA expression of the inflammatory marker chemokine ligand 1 (CXCL1) was measured in human total livers by *q*PCR. Neutrophil infiltration was measured by immunohistochemistry for myeloperoxidase (MPO) in paraffin-embedded mouse and human liver sections (4 μm thick) and *q*PCR for lymphocyte antigen 6 complex, locus G5C (Ly6G) in human total liver samples [40, 41].

Measurement of hepatic Cyp4a10, and Cyp4a11/22 in mouse and human liver sections

We measured the immunoreactivity of the following enzymes by which EtOH is metabolized in the liver [42]: (i) the mouse cytochrome P450, family 4, subfamily a, polypeptide 10 (Cyp4a10) in frozen mouse liver sections (4 μm thick); and (ii) the human homologous Cyp4a11/22 [42], by immunohistochemistry (paraffin-embedded) and immunofluorescence (frozen) in human liver sections (4 μm thick). Immunofluorescent staining was performed in mouse and human frozen liver (4 μm thick) sections co-stained with CK19 or HNF4 α . Immunofluorescence was visualized and quantified by the SP8 confocal microscope platform (Leica Microsystems Inc.). Since the expression of Cyp4a10 increases with EtOH feeding [42], we performed *q*PCR to determine the quantitative expression of Cyp4a10 in isolated mouse hepatocytes and cholangiocytes.

Measurement of Sct-dependent Elov11, total liver BA levels, and mRNA expression of genes regulating BA transport, metabolism and lipogenesis

The rationale for measuring Sct-dependent miR-125b is based on the fact that: (i) there is reduced expression of miR-125b in mouse models and human samples of early-stage PBC, PSC and NAFLD [12, 13, 17, 29]; and (ii) secretion triggers biliary damage through direct downregulation of miR-125b expression [12, 13, 17, 29]. The rationale for performing these experiments is based on our previous study showing that the Sct/miR-125b-dependent signaling axis promotes liver steatosis in mouse models of NAFLD by the up-regulation of the lipid biosynthesis gene, elongation of very-long-chain fatty acids 1 (Elov11) [29]. We measured: (i) the expression of miR-125b in mouse total liver samples by *q*PCR [29]; and (ii) the immunoreactivity of Elov11 by immunohistochemistry and/or immunofluorescence in mouse and human liver sections (4 μm thick) co-stained with CK19 or HNF4 α .

As an index of the degree of cholestasis, we measured the levels of hepatic total BAs (by a commercially available kit, catalog # 80,461, Crystal Chem, Elk Grove Village, IL) in total liver samples from WT and Sct^{-/-} mice fed either CD or EtOH. We have also measured the mRNA expression of genes regulating BA synthesis such as cholesterol 7 α -hydroxylase (Cyp27a1) and 12 α -hydroxylase (Cyp8b1), and the BA transporters, bile salt export pump (Bsep) and Na⁺-taurocholate cotransporting polypeptide (NTCP) in total mouse liver. The organic solute transporter alpha (OST α) was evaluated by immunofluorescence in frozen mouse liver sections (4 μm thick) co-stained with CK19 or HNF4 α .

Measurement of angiogenesis

Since Sct-dependent miR-125b regulates biliary functions through changes in vascular endothelial growth factor-A (VEGF-A) [12], we measured: (i) by immunohistochemistry the immunoreactivity of VEGF-A, platelet endothelial cell adhesion molecule (CD31), Roundabout 1 (Robo1, a receptor expressed by vascular endothelial cells that promotes angiogenesis and is linked to changes in DR), Slit2 in mouse and human liver sections (4 μm thick); (ii) by immunofluorescence the immunoreactivity of von Willebrand factor (vWF) and Robo1 in mouse frozen liver sections (4 μm thick) co-stained with CK19; and (iii) the mRNA expression of vWF in human total liver samples by *q*PCR.

Statistical analysis

All data are expressed as the mean \pm SEM. Differences between groups were analyzed by unpaired Student's *t*-test when two groups were analyzed and one-way ANOVA

when more than two groups were analyzed, followed by an appropriate post hoc test. The level of significance was set at $P < 0.05$. For data analysis GraphPad Prism Version 9.3.1 was used.

Results

Measurement of Sct/SR/CFTR/AE2 immunoreactivity/ expression in liver sections, Sct mouse and human serum levels, and bicarbonate bile levels in healthy controls and patients with alcoholic cirrhosis

By immunohistochemistry in mouse liver sections, we observed a significant increase in the immunoreactivity

of Sct, SR, and CFTR in EtOH-fed WT mice compared to CD-fed WT mice (Fig. 1A); no immunoreactivity (black star symbol) for Sct was observed in liver sections from CD- or EtOH-fed $Sct^{-/-}$ mice (Fig. 1A). The immunoreactivity of SR decreased in EtOH-fed $Sct^{-/-}$ mice compared to EtOH-fed WT mice (Fig. 1A). Sct mRNA expression was similar between CD-fed and EtOH-fed WT mice; as expected Sct mRNA expression was absent in CD-fed and EtOH-fed $Sct^{-/-}$ mice (Fig. 1B). There was increased SR mRNA expression in EtOH-fed WT compared to CD-fed WT mice, which decreased in EtOH-fed $Sct^{-/-}$ mice compared to EtOH-fed WT mice (Fig. 1B).




Fig. 1 **A** Sct, SR, and CFTR immunoreactivity significantly increased in EtOH-fed WT mice compared to CD-fed WT mice. The immunoreactivity of SR and CFTR decreased in EtOH-fed $Sct^{-/-}$ mice compared to EtOH-fed WT mice. Representative immunohistochemical images for Sct, SR, and CFTR in liver sections from CD-fed WT mice (n = 6), CD-fed $Sct^{-/-}$ mice (n = 4), EtOH-fed WT mice (n = 5), and EtOH-fed $Sct^{-/-}$ mice (n = 3) are shown. Orig. magn., 20X, scale bar: 100 μ m. Immunohistochemical quantification of Sct and SR in mouse liver sections. Data are mean \pm SEM of 5 random fields * $p < 0.05$ vs. CD-fed WT mice; # $p < 0.05$ vs. EtOH-fed WT mice. Each dot represents one value in data set. Black arrows indicate bile ducts, whereas black star symbols indicate bile ducts negative for Sct. **B** Sct mRNA expression was similar between CD-fed and EtOH-fed WT mice; Sct mRNA expression was absent in CD-fed and EtOH-fed $Sct^{-/-}$ mice. There was increased SR mRNA expression in EtOH-fed WT compared to CD-fed WT mice, which decreased in EtOH-fed $Sct^{-/-}$ mice compared to EtOH-fed WT mice. Data are mean \pm SEM of three PCR reactions from cholangiocytes from CD-fed WT mice (n = 6), CD-fed $Sct^{-/-}$ mice (n = 4), EtOH-fed WT mice (n = 5), and EtOH-fed $Sct^{-/-}$ mice (n = 3). * $p < 0.05$ vs. the values of CD-fed WT mice. # $p < 0.05$ vs. EtOH-fed WT mice

By immunohistochemistry for Sct and immunohistochemistry/immunofluorescence for SR, CFTR and AE2 in human liver sections, there was increased immunoreactivity of Sct, SR, CFTR, and AE2 in patients with alcoholic cirrhosis compared to healthy control livers (Figs. 2A–C and 3A–D). By immunoblots, there was a significant increase in SR (50–55 kDa) protein expression in total liver from patients with alcoholic cirrhosis (n=4) compared to the healthy controls (n=4) (Fig. 2D). Sct levels were significantly higher in serum from EtOH-fed WT mice and patients with alcoholic cirrhosis compared to their respective controls (Fig. 3E). There was a significant increase in bicarbonate levels in bile of human patients with alcoholic cirrhosis (n=9) compared to healthy controls (n=9) (Fig. 3F).

Depletion of Sct ameliorates liver injury and hepatic steatosis

LW/BW ratio (index of liver cell growth) [23] was higher in EtOH-fed WT mice compared to CD-fed WT mice, which was reduced in EtOH-fed Sct^{-/-} mice compared to EtOH-fed WT mice; no changes in LW/BW were observed among WT and Sct^{-/-} mice fed CD (Table 1). By H&E staining in liver sections, we observed increased steatosis and inflammation scores in EtOH-fed WT mice compared to CD-fed WT mice; these parameters were ameliorated in EtOH-fed Sct^{-/-} mice (Additional file 1: Fig. S1 and Table 1). Surprisingly, although CD-fed Sct^{-/-} mice were significantly heavier than CD-fed WT mice, these mice did not manifest significant hepatocyte steatosis. This may be due to the fact that the absence of Sct-induced bicarbonate secretion in the duodenum and small intestine of Sct^{-/-} mice favors absorption of sugar but impairs the absorption of fat [43, 44].

Depletion of Sct reduces DR, cholangiocyte and hepatocyte senescence and phenotypic switch of cholangiocytes and hepatocytes

There was increased DR in EtOH-fed WT mice compared to CD-fed WT mice, which was significantly decreased in EtOH-fed Sct^{-/-} mice compared to EtOH-fed WT mice; no changes in DR were observed between WT and Sct^{-/-} mice fed CD (Fig. 4A). By SA-β-gal staining,

and immunofluorescence for p16 in liver sections (co-stained with CK19 or HNF4α, respectively), there was a significant increase in cellular senescence of cholangiocytes and hepatocytes in EtOH-fed WT mice compared to CD-fed WT mice; these phenotypes were significantly decreased in EtOH-fed Sct^{-/-} mice (Fig. 4B–C). We also demonstrated: (i) increased biliary senescence (by SA-β-gal staining) in human liver sections; and (ii) enhanced mRNA expression of p18 (by qPCR) in total liver samples from patients with alcoholic cirrhosis compared to healthy control livers (Fig. 4D–E).

We also demonstrated that: (i) some periportal hepatocytes (positive for HNF4α) de novo express the biliary markers, CFTR and AE2, in liver sections from patients with alcoholic cirrhosis; and (ii) a subset of cholangiocytes de novo express BSEP in liver sections from EtOH-fed WT mice and patients with alcoholic cirrhosis (Fig. 5A–B). However, a previous study using in situ hybridization analysis demonstrated the expression of AE2 mRNA in some periportal human hepatocytes [45] suggesting that the expression of AE2 may be independent of EtOH administration. The data suggest that to compensate for the damage of a hepatocyte subpopulation (following EtOH feeding), a subset of cholangiocytes (likely small cholangiocytes that are more resistant to liver injury) [46] may acquire markers of hepatocytes and/or gradually acquire hepatocyte traits.

Depletion of Sct reduces liver fibrosis and HSC activation

There was enhanced collagen deposition in liver sections from EtOH-fed WT mice compared to CD-fed WT mice, which was significantly reduced in EtOH-fed Sct^{-/-} mice compared to EtOH-fed WT mice; no changes were observed between WT and Sct^{-/-} mice fed CD (Fig. 6A). In addition, there was increased immunoreactivity of desmin in mouse liver sections (co-stained with CK19) from EtOH-fed WT mice compared to CD-fed WT mice, which decreased in Sct^{-/-} EtOH-fed mice compared to EtOH-fed WT mice (Fig. 6B). In support of our findings, a previous study has shown that the hepatic expression of the fibrotic genes, α-smooth muscle actin (α-SMA) and TGFβ1 were upregulated in EtOH-fed WT mice compared to control mice [47].

(See figure on next page.)

Fig. 2 Sct and SR immunoreactivity increased in liver sections of patients with alcoholic cirrhosis compared to healthy control livers. **A** Sct and **B** SR immunoreactivity in human liver sections was examined by immunohistochemistry (4 healthy and 4 patients with alcoholic cirrhosis, from n=8 independent samples per group. Representative images are shown at orig. magn., 20X, scale bar = 100 μm. Immunohistochemical quantification of Sct and SR in human liver sections. Data are mean ± SEM of 5 random fields. *p < 0.05 vs. respective healthy control livers. Each dot represents one value in data set. Black arrows indicate bile ducts positive for Sct or SR, whereas white arrows indicate bile ducts positive for SR. **C** Immunofluorescence in liver sections co-stained with CK19 (SR staining from 2 healthy controls and 2 patients with alcoholic cirrhosis). Representative images are shown at orig. magn. 20X, scale bar: 100 μm. **D** By immunoblots, SR protein levels increased in total liver from patients with alcoholic cirrhosis (n=4) compared to human healthy controls (n=4). *p < 0.05 vs. healthy control livers. Data are mean ± SEM of three separate immunoblots from total liver from patients with alcoholic cirrhosis compared to human healthy controls




Fig. 2 (See legend on previous page.)

Depletion of Sct ameliorates macrophage and neutrophil infiltration

By immunohistochemistry in liver sections, we observed an increase in the number of (i) F4/80- and CD68-positive cells in EtOH-fed WT mice compared to CD-fed WT mice, which decreased in EtOH-fed *Sct*^{-/-} mice compared to EtOH-fed WT mice; and (ii) CD68 in liver samples from patients with alcoholic cirrhosis compared to the healthy control livers (Fig. 7A–B). The expression of the inflammatory marker, CXCL1, increased in total liver samples from patients with alcoholic cirrhosis compared to healthy controls (Fig. 7C). Additionally, immunohistochemistry for MPO in mouse and human liver sections showed that neutrophil infiltration was significantly increased in EtOH-fed WT mice and liver samples from patients with alcoholic cirrhosis compared to the relative control groups (Fig. 7D–E). EtOH-fed *Sct*^{-/-} mice displayed significantly decreased neutrophil infiltration compared to EtOH-fed WT mice (Fig. 7D). The expression of Ly6G (neutrophil infiltration marker) increased in liver samples from patients with alcoholic cirrhosis compared to healthy control livers (Fig. 7F).

Measurement of hepatic Cyp4a10 in mouse and Cyp4a11/22 in human samples

The rationale for measuring the immunoreactivity/expression of hepatic Cyp4a10 in mouse and Cyp4a11/22 in human samples is based on the background that these enzymes are vital for the metabolism of EtOH in the liver [42]. By immunofluorescence in mouse liver sections, we demonstrated enhanced immunoreactivity of Cyp4a10 in both cholangiocytes and hepatocytes from EtOH-fed WT mice compared to CD-fed WT mice; the immunoreactivity of Cyp4a10 was not reduced in EtOH-fed *Sct*^{-/-} mice compared to EtOH-fed WT mice (Fig. 8A). By qPCR, the mRNA expression of Cyp4a10 increased in both cholangiocytes and hepatocytes isolated from EtOH-fed WT mice compared to CD-fed WT mice but decreased in EtOH-fed *Sct*^{-/-} mice compared to EtOH-fed WT mice (Fig. 8B). Interestingly, we observed an increase in Cyp4a10 in hepatocytes from CD-fed *Sct*^{-/-} mice compared to CD-fed WT mice, which may be due

to a compensatory mechanism by hepatocytes due to the knock-out of Sct signaling, which may affect common transduction pathways (e.g., BA signaling) between cholangiocytes and hepatocytes. By immunofluorescence/immunohistochemistry in human liver sections, there was increased immunoreactivity of Cyp4a11/22 in patients with alcoholic cirrhosis (n=2) compared to healthy controls (n=2) (Fig. 8C). By immunohistochemistry there was increased immunoreactivity of Cyp4a11/22 in liver sections from patients with alcoholic cirrhosis (n=8) compared to healthy control livers (n=8) (Fig. 8C).

Measurement of Sct-dependent Elov11, total liver BA levels, mRNA expression of genes regulating BA transport, metabolism and lipogenesis

The rationale for measuring miR-125b in the present study is based on the fact that: (i) there is reduced expression miR-125b in mouse models and human samples of early-stage PBC, PSC and NAFLD [12, 13, 17, 29]; and (ii) Sct directly decreases the expression of miR-125b [12, 13, 17, 29]. The expression of miR-125b decreased in total liver from EtOH-fed WT mice compared to CD-fed WT mice and returned to normal values in *Sct*^{-/-} EtOH fed compared to EtOH-fed WT mice (Fig. 9A). By immunohistochemistry, we show that the hepatocyte immunoreactivity of Elov11 (a lipogenesis gene targeted by miR-125b) [29] increased in liver sections from EtOH-fed WT mice compared to CD-fed WT mice but decreased in EtOH-fed *Sct*^{-/-} mice compared to EtOH-fed WT mice. Parallel to a previous study [29], the expression of Elov11 was minimal in cholangiocytes (Fig. 9B). The hepatocyte immunoreactivity of Elov11 increases in liver sections from patients with alcoholic cirrhosis (n: 8) compared to healthy control livers (n: 8) (Fig. 9C). By immunofluorescence for Elov11/HNF4 α , there was increased hepatocyte Elov11 immunoreactivity in both mouse and human liver sections (Fig. 9D–E).

There was no significant difference in BA levels between WT mice fed CD or EtOH (18.54 \pm 3.19 mM vs. 32.84 \pm 7.02, respectively, p=0.14) (Table 1); however, BA levels were reduced in EtOH-fed *Sct*^{-/-} mice

(See figure on next page.)

Fig. 3 CFTR and AE2 immunoreactivity increased in liver sections of patients with alcoholic cirrhosis compared to healthy control livers.

Immunoreactivity of **A** CFTR and **C** AE2 was evaluated by immunohistochemistry in liver sections from 4 healthy controls and 4 patients with alcoholic cirrhosis. Representative images are shown at orig. magn., 20X, scale bar = 100 μ m. Immunohistochemical quantification of CFTR and AE2 in human liver sections. Data are mean \pm SEM of 5 random fields *p < 0.05 vs. relative controls. Each dot represents one value in data set. Immunoreactivity of **B** CFTR and **D** AE2 by evaluated by immunofluorescence in liver sections co-stained with CK19 (n = 2, Orig. magn. 20X, scale bar: 100 μ m) from healthy controls (n = 2) and patients with alcoholic cirrhosis (n = 2). Black and white arrows indicate bile ducts positive for CFTR and AE2. **E** Secretin levels increased in the serum from EtOH-fed WT mice and patients with alcoholic cirrhosis compared to respective control groups. Measurement of Sct serum levels from WT mice fed CD (n = 5) or EtOH (n = 4), and serum from human healthy controls (n = 6) and patients with alcoholic cirrhosis (n = 50). Data are mean \pm SEM of 3 experiments. *p < 0.05 vs. the respective control mouse and human samples. **F** There was a significant increase in bicarbonate levels in bile of human patients with alcoholic cirrhosis (n = 9) compared to healthy controls (n = 9). *p < 0.05 vs. healthy control livers




Fig. 3 (See legend on previous page.)

compared to EtOH-fed WT mice (Table 1). We also demonstrated increased mRNA expression of: (i) *Cyp27a1*, *Cyp8b1*, *Bsep* and *NTCP* in total liver samples from EtOH-fed WT mice compared to CD-fed WT mice,

which decreased in EtOH-fed *Sct*^{-/-} mice compared to EtOH-fed WT mice (Fig. 9F). By immunofluorescence for *Osta*/CK19 and *Osta*/HNF4 α , there was increased immunoreactivity of *Osta* in EtOH-fed WT

mice compared to CD-fed WT mice, which decreased in EtOH-fed Sct^{-/-} mice compared to EtOH-fed WT mice (Fig. 9G).

Loss of Sct reduces angiogenesis

By immunohistochemistry, we showed increased immunoreactivity of VEGF-A and CD31 in vascular cells, Robo1 (in both bile ducts and vascular cells), and Slit2 (in bile ducts) in EtOH-fed WT mice compared to CD-fed WT mice, which was decreased in EtOH-fed Sct^{-/-} mice (Fig. 10A). Robo1 immunoreactivity was confirmed by immunofluorescence in mouse liver sections co-stained with CK19 (Fig. 10B). By immunohistochemistry the immunoreactivity of the aforementioned angiogenic factors increased in liver sections from patients with alcoholic cirrhosis (n=8) compared to healthy control livers (n=8) (Fig. 10C). By vWF immunofluorescence in mouse liver sections, we found enhanced angiogenesis in EtOH-fed WT mice compared to CD-fed WT mice, which was reduced in EtOH-fed Sct^{-/-} mice (Fig. 10B). By qPCR in total liver, we showed that the mRNA expression of angiogenesis marker vWF increased in patients with alcoholic cirrhosis compared to healthy controls (Fig. 10D).

Discussion

In the present study, we demonstrated upregulation of Sct/SR signaling in ALD evidenced by: (i) enhanced immunoreactivity/expression of Sct/SR/CFTR in an ALD mouse model and Sct/SR/CFTR/AE2 axis in liver sections from patients with alcoholic cirrhosis; and (ii) higher levels of Sct in serum from EtOH-fed WT mice as well as patients with alcoholic cirrhosis and higher bicarbonate levels in bile from patients with alcoholic cirrhosis compared to the respective controls. We demonstrated enhanced DR, biliary senescence (that activates HSCs by a paracrine mechanism mediated by the biliary secretion of TGFβ1) [16], liver inflammation and fibrosis, infiltration of neutrophils, and liver angiogenesis in EtOH-fed WT mice compared to CD-fed WT mice, phenotypes that were reduced in EtOH-fed Sct^{-/-} mice. Parallel to the findings obtained in the mouse groups, we

show enhanced DR and biliary senescence in liver samples from patients with alcoholic cirrhosis compared to healthy control livers. Concerning the expression of the enzymes metabolizing alcohol in the liver [42], we demonstrated that: (i) mouse cholangiocytes express Cyp4a10 whose immunoreactivity is increased in EtOH-fed WT mice (compared to controls) but decreased in EtOH-fed Sct^{-/-} mice. Human cholangiocytes express Cyp4a11/22, which is upregulated in the total liver from patients with alcoholic cirrhosis compared to healthy controls. EtOH-induced changes in biliary and liver phenotypes were associated with reduced biliary miR-125b expression, which facilitates the enhanced expression of hepatocyte Elov11 expression as observed in mouse models and human samples of NAFLD [29], and subsequently ALD phenotypes.

The Sct/SR signaling axis is paramount in regulating biliary homeostasis and adaptive changes occurring during cholestasis [16]. For example, in the Mdr2^{-/-} mouse model of chronic cholestasis together with correlative experiments in human late-stage PSC liver samples, we demonstrated enhanced activity of Sct/SR signaling, which in turn activates the TGFβ1 axis triggering activation of HSCs with subsequent enhanced deposition of fibrotic matrix [9]. Recently, we have expanded these findings and evaluated the role of the biliary Sct/SR axis in liver diseases such as NAFLD and NASH. We demonstrated that Sct/SR signaling stimulates lipid accumulation via Sct-dependent downregulation of biliary miR-125b that induced lipogenesis in high fat diet (HFD)-fed mice through upregulation of hepatocyte Elov11 [29]. Similarly, while upregulation of Sct signaling and Sct serum levels (observed in early-stage models of PBC and early-stage PBC patients) promotes DR, biliary damage and liver fibrosis [13], downregulation/loss of Sct expression/secretion (which leads to decreased bicarbonate secretion, “bicarbonate umbrella”) occurs in ductopenic diseases such as late-stage PBC [15, 21, 48]. Our studies introduce the concept that proper Sct levels maintain biliary homeostasis and liver functions. Our current findings support the idea that excessive expression levels of

(See figure on next page.)

Fig. 4 Knockout of Sct ameliorates DR and senescence in EtOH-fed mice. **A** There was a significant increase in DR in EtOH-fed WT mice compared to CD-fed WT mice, which was significantly decreased in EtOH-fed Sct^{-/-} mice compared to EtOH-fed WT mice. Data are mean ± SEM of 5 experiments from CD-fed WT mice (n=6), WT fed-EtOH mice (n=5), CD-fed Sct^{-/-} mice (n=4) and EtOH-fed Sct^{-/-} mice (n=3), Orig. magn., 20X, scale bar: 100 μm. *p < 0.05 vs. CD-fed WT mice; #p < 0.05 vs. EtOH-fed WT mice. Red arrows indicate the bile ducts positive for CK19. **B–C** Measurement of cellular senescence in liver sections by **B**) SA-β-gal staining (Orig. magn., 20X, scale bar: 100 μm) and **C**) immunofluorescence for p16 in liver sections (co-stained with CK19 or HNF4α, respectively). Orig. magn., 20X, scale bar: 100 μm; Black arrows indicate senescent bile ducts, whereas white arrows indicate p16 positivity of cholangiocytes or hepatocytes. **D** By SA-β-Gal there was enhanced biliary senescence in liver sections from patients with alcoholic cirrhosis (n=4) compared to human healthy controls (n=3); orig. magn 20X, scale bar: 100 μm. Data are mean ± SEM of 5 random fields *p < 0.05 vs. healthy controls. Representative images in liver sections from patients with alcoholic cirrhosis (n=3) and healthy controls (n=3). Black arrows indicate senescent bile ducts. **E** By qPCR, there enhanced mRNA expression of p18 in total liver samples from patients with alcoholic cirrhosis (n=16) compared to healthy controls (n=10). Data are mean ± SEM of two experiments for each sample. *p < 0.05 vs healthy controls




Fig. 4 (See legend on previous page.)

Sct trigger hepatobiliary damage, whereas downregulation of Sct signaling (which is detrimental in ductopenic stages) [15, 21, 48] ameliorates aberrant biliary phenotypes including senescence, liver inflammation, fibrosis, neutrophil infiltration, and angiogenesis in ALD.

Excessive consumption of alcohol is a significant cause of human liver diseases and mechanisms leading to alcohol-induced cholestasis during ALD are undefined [11]. Since cholestasis is a clinical feature of ALD [11] and Sct is a key regulator of cholestasis in liver diseases [16], we studied the role of the Sct/SR signaling axis during EtOH feeding and in human liver samples from patients with alcoholic cirrhosis. Several typical pathological features of alcohol-induced liver damage (observed in EtOH-fed WT mice) such as liver inflammation, DR, cholestasis, biliary and hepatocyte senescence, liver angiogenesis, steatosis, and fibrosis were ameliorated in Sct^{-/-} mice demonstrating an impactful relationship between Sct stimulation and the subsequent onset of pathological features after EtOH exposure. Similar to cholestatic conditions, EtOH liver damage up-regulates Sct signaling that, when chronically maintained, gives rise to DR-associated cellular senescence, which induces inflammation and fibrosis. While the increase in Sct serum levels (observed in patients with alcoholic cirrhosis) supports the concept that Sct triggers hepatobiliary damage and liver fibrosis, the increase in HCO₃⁻ levels in bile samples (although not significant) from patients with alcoholic cirrhosis may be due to a compensatory secretory repair mechanism by adjacent non-senescent cholangiocytes which may secrete HCO₃⁻ by Ca²⁺-dependent Cl⁻ channels (e.g., transmembrane member 16A (TMEM16A) [49] independent of cAMP signaling, however, further studies are necessary to support this concept.

After we established that downregulation of the Sct/SR signaling axis reduces liver fibrosis and steatosis with decreased DR/biliary senescence likely by paracrine signaling, we evaluated the mechanisms by which cholangiocytes metabolize EtOH inducing changes in biliary and liver phenotypes. In addition to the metabolism of EtOH by hepatocytes (mediated by Cyp4a10 [mouse] and Cyp4a11/22 [human]) [42], our data also demonstrate that cholangiocytes may metabolize EtOH through the enzymes, Cyp4a10 and Cyp4a11/22 (whose expression is increased in EtOH-fed WT mice and liver

samples from patients with alcoholic cirrhosis). These biliary/liver phenotypes were ameliorated in EtOH-fed Sct^{-/-} mice, associated with a concomitant decreased expression of Cyp4a10 and Cyp4a11A22 in cholangiocytes and Cyp4a11/22 in hepatocytes [42]. Supporting our findings, several studies have emphasized the expression of metabolizing enzymes in bile ducts and the role of cholangiocytes in the clearance of liver toxins [46]. A single dose of carbon tetrachloride (CCl₄) induces apoptosis of large cholangiocytes since they express the enzyme, cytochrome P-450E1, which converts CCl₄ to free-radical species such as trichloromethyl free radicals [50]. During CCl₄-induced damage to large cholangiocytes, small cholangiocytes (which do not express cytochrome P-450E1 and are resistant to CCl₄-induced damage) de novo express markers of large cholangiocytes (i.e., SR) and proliferate to maintain homeostatic biliary mass [50]. Furthermore, hyperplastic cholangiocytes lining interlobular ducts of cholestatic BDL rats express Phase II (UDP-glucuronosyltransferase and glutathione S-transferase) but not Phase I enzymes. The expression of Phase II enzymes in interlobular bile ducts may alter the resistance of these ducts to the cytotoxic effects of hepatotoxins [46].

Our data suggests that changes in the expression of the Sct-dependent signaling may be necessary for the modulation of liver injury. In agreement with this concept, several studies demonstrated that the effects of the Sct/SR signaling axis on biliary damage and liver fibrosis are mediated by paracrine modulation of TGFβ1 biliary secretion that leads to activation/deactivation of HSCs and changes in liver fibrosis through modulation of liver angiogenesis [9, 16, 17]. Specifically, Sct stimulates DR and liver fibrosis (by a paracrine loop) in cholestatic models by enhanced biliary secretion of TGFβ1. In contrast, downregulation of Sct/SR signaling reduces DR/biliary senescence, liver angiogenesis and liver fibrosis by downregulation of TGFβ1 [9, 16, 17]. Consistent with our previous studies, we show that EtOH feeding triggers angiogenesis, increasing the expression of angiogenic factors (that activates liver fibrosis) in WT mice, which was decreased in EtOH-fed Sct^{-/-} mice.

We next evaluated the mechanisms by which changes in biliary Sct signaling (following EtOH feeding) may

(See figure on next page.)

Fig. 5 A Some periportal hepatocytes de novo expresses the biliary markers, CFTR and AE2 in liver sections from patients with alcoholic cirrhosis, whereas a subset of cholangiocytes de novo express BSEP in liver sections from EtOH-fed WT mice and patients with alcoholic cirrhosis; representative images from human liver sections from healthy controls (n = 2) and patients with alcoholic cirrhosis (n = 2). For immunofluorescent staining for CFTR and AE2, orig. magn., 20X, scale bar: 100 μm; white arrows show hepatocytes which de novo express CFTR and AE2. **B** Representative immunofluorescence images for BSEP/CK19 from CD-fed WT mice (n = 4), and EtOH-fed WT mice (n = 5), as well as human healthy controls (n = 2) and patients with alcoholic cirrhosis (n = 2), orig. magn. 20X, scale bar: 100 μm. White arrows indicate the cholangiocytes that de novo express BSEP




Fig. 5 (See legend on previous page.)




Fig. 6 Knockout of Sct ameliorates liver fibrosis in EtOH-fed mice. **A** Measurement of collagen deposition by Sirius Red/Fast Green. Orig., magn. 20X, scale bar: 100 μ m. For bar graphs, data are mean \pm SEM, * p < 0.05 vs. CD-fed WT mice; # p < 0.05 vs. EtOH-fed WT mice. **B** Representative immunofluorescence images for desmin in liver sections co-stained with CK19 from CD-fed WT mice ($n = 6$), EtOH-fed WT mice ($n = 5$), CD-fed Sct^{-/-} mice ($n = 4$), and EtOH-fed Sct^{-/-} mice ($n = 4$). Orig. magn. 20X, scale bar: 100 μ m. White arrows indicate bile ducts positive for desmin

contribute to changes in hepatic steatosis through paracrine mechanisms mediated by Sct. Similar to our previous studies in a mouse model of NAFLD [29], we demonstrated that chronic EtOH feeding increases Sct levels and Sct/SR signaling that decreases the biliary expression of miR-125b, which in turn increases the expression of the lipogenesis target gene, Elov11 (expressed mostly in hepatocytes and at low levels by cholangiocytes) triggering hepatocyte lipid accumulation and hepatic steatosis. Supporting this concept, several studies demonstrated the critical role of ELOVL family in the modulation of liver injury in mouse models of NAFLD and ALD. For example, in Pten null mouse livers, there is increased expression of Elov11 and Elov6, which are associated with enhanced lipogenesis [51]. The hepatocyte Elov6 has been shown to regulate ceramide acyl-chain length and hepatic insulin sensitivity in mice linked to Pnpla3-mediated NAFLD [52]. Further, studies have shown that Elov6 promotes NAFLD, whereas absence of

Elov6 ameliorates steatohepatitis in a lithogenic diet-fed LDL receptor-deficient mouse model [53, 54]. Moreover, Elov6 expression increases in murine models of chronic alcohol administration [55, 56]. Additionally, Elov5 regulates hepatic triglyceride catabolism in obese C57BL/6 J mice [57]. Future studies are needed to better demonstrate this pathway in our mouse ALD models.

Regarding angiogenesis, a number of studies suggest that cross-talk signaling between the biliary epithelium and the peribiliary vascular plexus (that nourishes the biliary epithelium) [58] coordinately modulate biliary proliferation/damage and liver fibrosis during cholestatic liver injury [13, 29, 58–60]. Our findings support the concept that liver angiogenesis (mediated by Sct/SR signaling) is an essential regulator of DR, liver fibrosis, and steatosis in cholangiopathies. Indeed, Sct effects on biliary and liver phenotypes have been shown to be mediated by changes in the expression of angiogenic factors regulated by the Sct/SR signaling axis [9, 12, 13, 16, 29]. This concept is




Fig. 7 **A** Immunohistochemistry for the macrophage-specific markers, F4/80 and **B** CD68, in liver sections from the selected mouse groups ($n \geq 3$ /group) as well as healthy controls ($n = 8$), and patients with alcoholic cirrhosis ($n = 8$). Orig., magn. 10X; scale bar: 100 μm . For bar graphs, data are of 5 random fields mean \pm SEM, * $p < 0.05$ vs. the respective control groups; # $p < 0.05$ vs. EtOH-fed WT mice. **C** qPCR for CXCL1 in total liver samples from healthy controls ($n = 6$) and patients with alcoholic cirrhosis ($n = 16$). Data are mean \pm SEM. * $p < 0.05$ vs. healthy control samples. **D** Immunohistochemistry for MPO in liver sections from the selected groups of mice ($n \geq 3$ /group), healthy controls ($n = 8$), and patients with alcoholic cirrhosis ($n = 8$). Orig. magn. 20X for mouse and 10X for human, scale bar: 100 μm . **E** Immunohistochemical quantification of MPO in human liver sections. Data are mean \pm SEM of 5 random fields. * $p < 0.05$ vs. healthy controls. **F** qPCR for the neutrophil marker, Ly6G, in healthy controls ($n = 6$) patients with alcoholic cirrhosis ($n = 16$). Data are mean \pm SEM of two experiments for each sample. * $p < 0.05$ vs healthy control samples. Black arrows indicate MPO⁺ positive cells




Fig. 8 Cyp4a10 and Cyp4a11/12 are expressed by mouse and human cholangiocytes and hepatocytes, respectively. **A** Measurement of immunoreactivity for Cyp4a10 in liver sections (co-stained with CK19 or HNF4a) from selected mouse groups ($n \geq 3$ /group) by immunofluorescence. Orig. magn. 20X, scale bar: 100 μ m. There was enhanced biliary immunoreactivity of Cyp4a10 in EtOH-fed WT mice compared to CD-fed WT mice. The Cyp4a10 positive area % refers to both cholangiocytes and hepatocytes immunoreactive for Cyp4a10. * $p < 0.05$ vs. CD-fed WT mice; # $p < 0.05$ vs. EtOH-fed WT mice. **B** In EtOH-fed WT mice, there was enhanced expression of Cyp4a10 (in isolated hepatocytes and cholangiocytes) compared to CD-fed WT mice, which was reduced in EtOH-fed Sct^{-/-} mice. Data are mean \pm SEM of 3 experiments from selected mice groups ($n \geq 3$ /group). * $p < 0.05$ vs. CD-fed WT mice; # $p < 0.05$ vs. EtOH-fed WT mice. **C** Measurement of immunoreactivity for Cyp4a11/22 in liver sections (co-stained with CK19 or HNF4a) from human healthy controls ($n = 2$) and patients with alcoholic cirrhosis ($n = 2$) by immunofluorescence; immunoreactivity of Cyp4a11/22 was measured in paraffin-embedded liver sections from human control ($n = 8$) and patients with alcoholic cirrhosis ($n = 8$) by immunohistochemistry. Orig. magn. 20X, scale bar: 100 μ m. White arrows indicate Cyp4a10- and Cyp4a11/22- positive cells. Black arrows show Cyp4a11/22-positive cells

supported by several studies showing that angiogenic factors, such as VEGF-A stimulate biliary proliferation, liver fibrosis and lipogenesis associated with increased hepatic steatosis in cholestatic models [59, 61, 62].

A limitation of our study is represented by the fact that we do not evaluate the downstream Sct-dependent signaling pathways in cholangiocytes that may partly explain the paracrine effect on hepatocyte EtOH metabolism.

The rationale for measuring the levels of total BAs and the mRNA expression of genes regulating BA synthesis and transport in mouse and human liver samples is based on the findings that there is synergistic interaction between Sct and BA signaling. For example, we have shown [15] that treatment of a late stage mouse model of PBC (dominant-negative TGFb receptor II, dnTGFbRII at 32 wk of age) with Sct for 8 wk reduced hepatic total BA content and induced in female dnTGFbRII mice a significant reduction in taurine-conjugated b-muricholic acid, an antagonist of farnesoid X receptor, which after BA activation regulates bile acid synthesis, metabolism, and transport [63]. Furthermore, treatment of male dnTGFbRII mice (32 wk age) with Sct for 8 weeks reduced

the levels of taurine-conjugated cholic acid and increased taurine-conjugated chenodeoxycholic acid content; these data suggest that Sct signaling play an important role in the regulation of cholehepatic shunting and the associated total BA clearance [15]. In addition, in mice fed HFD for 16 wk, knockout of the Sct/SR signaling axis induced an increase in total bile acid fecal excretion, altered total liver BA composition and induced an increase in serum BA levels compared to WT mice fed HFD [29]. Supporting the role of Sct in the modulation of BA signaling, our current data have shown an increase in the mRNA expression genes regulating BA synthesis (Cyp27a1, Cyp8b1 and Cyp7b11), and BA transporters (Bsep, NTCP and OSTa) in liver samples from EtOH-fed WT mice compared to CD-fed WT mice, which decreased in EtOH-fed Sct^{-/-} mice compared to EtOH-fed WT mice. Supporting a possible feed-back mechanism between Sct and BAs, a study has shown that Sct has been shown to stimulate cholehepatic shunting of conjugated BAs through increased expression of the apical sodium-BA transporter (ASBT) [64]. Furthermore, the BAs ursodeoxycholate and tauroursodeoxycholate




Fig. 9 Elov1 is expressed in hepatocytes and at low levels in cholangiocytes from mouse and human livers. **A** The expression of miR-125b in mouse liver ($n \geq 3$) was evaluated by qPCR. For bar graphs, data are mean \pm SEM of 3 replicates from CD-fed WT mice ($n = 5$), EtOH-fed WT mice ($n = 5$), CD-fed Sct^{-/-} mice ($n = 5$), and EtOH-fed Sct^{-/-} mice ($n = 4$). * $p < 0.05$ vs. CD-fed WT mice; # $p < 0.05$ vs. EtOH-fed WT mice. **B–C** Representative images for Elov1 in liver sections from **B** the selected mouse groups ($n \geq 3$ /group), **C** healthy human controls ($n = 8$) and patients with alcoholic cirrhosis ($n = 8$) by immunohistochemistry. Scale bar: 100 μ m. Immunohistochemical quantification of Elov1 in human liver sections. Data are mean \pm SEM of 5 random fields * $p < 0.05$ vs. controls. **D–E** Immunofluorescence of Elov1 in liver sections (co-stained with HNF4a) from **D** the selected mouse groups ($n \geq 3$ /group); orig. magn. 20X, scale bar: 100 μ m. **E** human healthy controls ($n = 2$) and patients with alcoholic cirrhosis ($n = 2$). Orig. magn. 20X, scale bar: 100 μ m. White arrows indicate Elov1 positivity. **F** Measurement of Cyp27a1 and Cyp7b1 genes (which regulate BA synthesis), and the BA transporters genes, Bsep and NTCP, in total mouse liver. We demonstrated increased mRNA expression of Cyp27a1, Cyp8b1, Bsep and NTCP in total liver from EtOH-fed WT mice compared to CD-fed WT mice, which were decreased in EtOH-fed Sct^{-/-} mice compared to EtOH-fed WT mice. Data are mean \pm SEM of three qPCR reactions from mouse total liver samples from CD-fed WT mice ($n = 5$), CD-fed Sct^{-/-} mice ($n = 3$), EtOH-fed WT mice ($n = 5$), and EtOH-fed Sct^{-/-} mice ($n = 5$) for Cyp27a1, Cyp8b1 mRNA expression, and CD-fed WT mice ($n = 4$), CD-fed Sct^{-/-} mice ($n = 4$; 6 experiments), EtOH-fed WT mice ($n = 5$), and EtOH-fed Sct^{-/-} mice ($n = 4$) for Bsep and NTCP mRNA expression. **G** By immunofluorescence for Osta/CK19 and Osta/HNF4a, there was increased immunoreactivity of Osta in EtOH-fed WT mice compared to CD-fed WT mice, which decreased in EtOH-fed Sct^{-/-} mice compared to EtOH-fed WT mice. The selected mouse groups ($n \geq 3$ /group); orig. magn. 20X, scale bar: 100 μ m. White arrows indicate Osta positivity.

inhibit biliary proliferation, ductal secretion, cAMP levels, and ASBT expression through phosphorylation of the Ca²⁺-dependent protein kinase alpha [65]. Moreover, the BAs, cholic acid and chenodeoxycholic acid, have been shown to inhibit duodenal secretin expression through increased expression of orphan nuclear receptor small heterodimer partner [66]. A limitation of our studies

is the fact that we have used total Sct^{-/-} mouse ALD models that do not exclude the possibility that changes in hepatic steatosis may be due to impaired intestinal lipid absorption; however, we have developed a cholangiocyte-specific SR^{-/-} mouse model that we will use in future




Fig. 10 Alcohol-induced liver angiogenesis is decreased in EtOH-fed *Sct*^{-/-} mice. **A** Paraffin-embedded liver sections were stained with VEGF-A, CD31, Robo1, and Slit2 to evaluate liver angiogenesis in the selected mouse liver ($n \geq 3$ /group). Orig. magn. 20X, scale bar: 100 μ m. **B** The immunoreactivity of Robo1 and vWF was evaluated in mouse liver sections co-stained with CK19 ($n \geq 3$) by immunofluorescence. Orig. magn. 20X, scale bar: 100 μ m. **C** The immunoreactivity of VEGF-A, CD31, Robo1, and Slit2 was examined in paraffin-embedded liver sections from human control ($n = 8$) and patients with alcoholic cirrhosis ($n = 8$) by immunohistochemistry. Orig. magn. 20X, scale bar: 100 μ m Immunohistochemical quantification of VEGF-A, CD31 and Robo1 in human liver sections. Evaluation of Robo1 staining data is mean \pm SEM of 5 random fields * $p < 0.05$ vs. Control. **D** mRNA expression of vWF was evaluated in total liver from healthy controls ($n = 6$) and patients with alcoholic cirrhosis ($n = 16$) by qPCR. For bar graphs, data are mean \pm SEM, * $p < 0.05$ vs. relative controls

experiments to pinpoint the role of biliary *Sct*/SR signaling on liver phenotypes [43].

Our study introduces the concept that, in addition to the direct effects of EtOH on hepatocyte functions [42], alcohol feeding induces changes in *Sct*-dependent biliary phenotypes which contributes to liver fibrosis and lipogenesis and subsequently hepatocyte steatosis which is in keeping with our previous study in animal models of NAFLD (29). Modulating the *Sct*/SR axis may be important to modulate DR/biliary senescence and liver fibrosis and regulate hepatocyte lipogenesis/steatosis and liver angiogenesis by paracrine pathways (Additional file 2: Fig. S2). In this perspective, down-regulation of the *Sct*/SR pathway might also benefit chronic liver diseases.

Abbreviations

AE2 Anion exchanger 2
ALD Alcoholic-related liver diseases

α -SMA α -Smooth muscle actin
BA Bile acid
BDL Bile duct ligation
BSEP Hepatocyte bile salt export pump
cAMP Adenosine 3',5'-cyclic monophosphate
CD Control diet
CD31 Platelet endothelial cell adhesion molecule
CD68 Cluster of differentiation 68
CFTR Cystic fibrosis transmembrane conductance regulator
CK19 Cytokeratin 19
Cyp4a Cytochrome P450 4A
CYP7A1 Cholesterol 7 α -hydroxylase
Cyp8b1 12A-hydroxylase
Cyp27a1 Sterol 27-hydroxylase
CYP7B1 Oxysterol 7 α -hydroxylase
CXCL1 Chemokine ligand 1
DAPI 4',6-diamidino-2-phenylindole
DR Ductular reaction
Elovl1 Elongation of very-long-chain fatty acids 1
EtOH Ethanol
H&E Hematoxylin and eosin
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
HNF4 α Hepatocyte nuclear factor α
HSCs Hepatic stellate cells

HIBEpiC	Human normal intrahepatic biliary epithelial cell
IL	Interleukin
Ly6G	Lymphocyte antigen 6 complex, locus G
Mdr2 ^{-/-}	Multidrug resistance protein 2
miRNA	Micro-RNA
MPO	Myeloperoxidase
MRP3	Multidrug resistance-associated protein 3
NAFLD	Nonalcoholic fatty liver disease
NASH	Non-alcoholic steatohepatitis
NTCP	Na ⁺ -taurocholate cotransporting polypeptide
OSTa	Organic solute transporter a
PBC	Primary biliary cholangitis
PCNA	Proliferating cellular nuclear antigen
p16	Cyclin-dependent kinase inhibitor 2A
p18	Cyclin-dependent kinase inhibitor 2C
PSC	Primary sclerosing cholangitis
qPCR	Quantitative polymerase chain reaction
SA-β-gal	Senescence-associated-β-galactosidase
Sct	Secretin
SR	Secretin receptor
TGFβ1	Transforming growth factor β1
VEGF-A	Vascular endothelial growth factor-A
vWF	Von Willebrand factor
WT	Wild-type

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13578-022-00945-w>.

Additional file 1: Figure S1. Knockout of Sct ameliorates liver damage compared to EtOH-fed WT mice. Representative images and evaluation of liver histology by H&E staining in paraffin-embedded liver sections from CD-fed WT mice (n=6), CD-fed Sct^{-/-} mice (n=4), EtOH-fed WT mice (n=5), and EtOH-fed Sct^{-/-} mice (n=3). There was increased liver damage in EtOH-fed WT mice compared to CD-fed WT mice, phenotypes that were ameliorated in EtOH-fed Sct^{-/-} mice compared to EtOH-fed WT mice. Orig. magn., 20X, scale bar = 100 μm.

Additional file 2: Figure S2. Working model: Alcohol consumption increases Sct/SR signaling axis in cholangiocytes, which through down-regulation of miR-125 mechanism stimulates VEGF-A and trigger DR/ biliary senescence, liver inflammation and fibrosis in the liver. The connection between Sct/SR signaling axis and Cyp4a10 enzyme regulates not only liver fibrosis but also hepatic steatosis through paracrine mechanisms regulated by the miR-125b/Elov1 signaling axis inducing changes in lipogenesis. Knock-out of the Sct/SR axis ameliorates these liver phenotypes. Created with Biorender.com.

Additional file 3: Table S1. List of mouse and human primers for PCR.

Additional file 4: Table S2. List of antibodies.

Additional file 5: Table S3. Characteristics of healthy controls and ALD patients for liver, bile and cholangiocytes.

Additional file 6: Table S4. Characteristics of healthy controls and ALD patients for serum.

Acknowledgements

This material results from work supported by resources at the Richard L. Roudebush VA Medical Center, Indianapolis, IN, and Texas A&M University, Department of Medical Physiology, Medical Research Building, Bryan, TX. The views expressed in this article are those of the authors and do not necessarily represent the Department of Veterans Affairs views.

Author contributions

KK: drafted the manuscript and revised it critically for important intellectual content; substantial conceptual and design contributions, acquisition of data, analysis, generation of figures, and interpretation of data. NW: substantial contributions to acquisition of data and interpretation of data; generation of figures, revised the article critically for important intellectual content. TZ:

substantial contributions to acquisition of data and interpretation of data; revised the article critically for important intellectual content. GC: substantial contributions to acquisition of data and interpretation of data; revised the article critically for important intellectual content. LB: substantial contributions to interpretation of data; revised the article critically for important intellectual content. LK: substantial contributions to acquisition of data and interpretation of data; revised the article critically for important intellectual content. LC: substantial contributions to acquisition of data and interpretation of data; revised the article critically for important intellectual content. AM: substantial contributions to animal colony management, acquisition of data and interpretation of data. NB: substantial contributions to acquisition of data and interpretation of data; revised the article. AF: substantial contributions to interpretation of data; revised the article. PO: substantial contributions to interpretation of data; revised the article. BE: substantial contributions to obtain human samples, acquisition of data and interpretation of data; revised the article. EG: substantial contributions to interpretation of data; revised the article. CW: substantial contributions to interpretation of data; revised the article. CM: substantial contributions to interpretation of data; revised the article. SC: substantial contributions to interpretation of data; revised the article. HF: substantial conceptual and design contributions, and interpretation of data; revised the article critically for important intellectual content. SG: substantial conceptual and design contributions, and interpretation of data; revised the article critically for important intellectual content. GA: substantial conceptual and design contributions, data analysis and interpretation of data; drafted the article and revised it critically for important intellectual content. All authors read and approved the final manuscript.

Funding

This work was supported by the Hickam Endowed Chair, Gastroenterology, Medicine, Indiana University, the Indiana University Health—Indiana University School of Medicine Strategic Research Initiative, the Senior Career Scientist Award (IK6 BX004601) and the VA Merit award (5I01BX000574) to GA and the Career Scientist Award (IK6BX005226) and the VA Merit award (1I01BX003031) to HF, and Career Development Award-2 to LK (1IK2BX005306) from the United States Department of Veteran's Affairs, Biomedical Laboratory Research and Development Service and Development Service and the NIH grants DK108959 and DK119421 (HF), DK054811, DK115184, DK076898, DK107310, DK110035, DK062975, AA028711 to Drs. Alpini, and Glaser.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Human tissues were obtained under a protocol approved by the Institutional Review Board (IRB) at Indiana University School of Medicine. Animal procedures were performed following protocols approved by the Indiana University School of Medicine Institutional Animal Care and Use Committees.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. ²Department of Anatomical, Histological, Forensic Medicine and Orthopedics Sciences, La Sapienza University of Rome, Rome, Italy. ³Unit of Hepatology, Tor Vergata University, Rome, Italy. ⁴Division of Research, Indiana Center for Liver Research, Gastroenterology, Medicine, Richard L. Roudebush VA Medical Center and Indiana University, 702 Rotary Circle, Rm. 013C, Indianapolis, IN 46202-2859, USA. ⁵Department of Movement, Human and Health Sciences, University of Rome "Foro Italico", Rome, Italy. ⁶Division of Transplant Surgery, Department of Surgery, Indiana University, Indianapolis, IN, USA. ⁷Department of Nutrition, Texas A&M University, College Station, TX, USA. ⁸Department

of Medical Physiology, Texas A&M University School of Medicine, 8447 Riverside Parkway, MREB II, Room 2342, Bryan, TX 77807-3260, USA.

Received: 17 June 2022 Accepted: 19 December 2022

Published online: 09 January 2023

References

- Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG clinical guideline: alcoholic liver disease. *Am J Gastroenterol*. 2018;113(2):175–94.
- Glaser T, Baiocchi L, Zhou T, Francis H, Lenci I, Grassi G, et al. Pro-inflammatory signalling and gut-liver axis in non-alcoholic and alcoholic steatohepatitis: Differences and similarities along the path. *J Cell Mol Med*. 2020;24(11):5955–65.
- Satishchandran A, Ambade A, Rao S, Hsueh YC, Iracheta-Vellve A, Tornai D, et al. MicroRNA 122, regulated by GRLH2, protects livers of mice and patients from ethanol-induced liver disease. *Gastroenterology*. 2018;154(1):238–52 e7.
- Kim SJ, Feng D, Guillot A, Dai S, Liu F, Hwang S, et al. Adipocyte death preferentially induces liver injury and inflammation through the activation of chemokine (C-C Motif) receptor 2-positive macrophages and lipolysis. *Hepatology*. 2019;69(5):1965–82.
- Mandache E, Vidulescu C, Gherghiceanu M, Dragomir P, Popescu LM. Neoductular progenitor cells regenerate hepatocytes in severely damaged liver: a comparative ultrastructural study. *J Cell Mol Med*. 2002;6(1):59–73.
- Blaya D, Coll M, Rodrigo-Torres D, Vila-Casadesus M, Altamirano J, Llopis M, et al. Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. *Gut*. 2016;65(9):1535–45.
- Sancho-Bru P, Altamirano J, Rodrigo-Torres D, Coll M, Millan C, Jose Lozano J, et al. Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. *Hepatology*. 2012;55(6):1931–41.
- Sato K, Marzioni M, Meng F, Francis H, Glaser S, Alpini G. Ductular reaction in liver diseases: pathological mechanisms and translational significances. *Hepatology*. 2019;69(1):420–30.
- Wu N, Meng F, Invernizzi P, Bernuzzi F, Venter J, Standeford H, et al. The secretin/secretin receptor axis modulates liver fibrosis through changes in transforming growth factor-beta1 biliary secretion in mice. *Hepatology*. 2016;64(3):865–79.
- Zhou T, Kyritsi K, Wu N, Francis H, Yang Z, Chen L, et al. Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2^(-/-) mouse model of primary sclerosing cholangitis (PSC). *EBioMedicine*. 2019;48:130–42.
- Jungst C, Berg T, Cheng J, Green RM, Jia J, Mason AL, et al. Intrahepatic cholestasis in common chronic liver diseases. *Eur J Clin Invest*. 2013;43(10):1069–83.
- Glaser S, Meng F, Han Y, Onori P, Chow BK, Francis H, et al. Secretin stimulates biliary cell proliferation by regulating expression of microRNA 125b and microRNA let7a in mice. *Gastroenterology*. 2014;146(7):1795–808 e12.
- Kennedy L, Francis H, Invernizzi P, Venter J, Wu N, Carbone M, et al. Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis. *FASEB J*. 2019;33(9):10269–79.
- Wu N, Carpino G, Ceci L, Baiocchi L, Francis H, Kennedy L, et al. Melatonin receptor 1A, but not 1B, knockout decreases biliary damage and liver fibrosis during cholestatic liver injury. *Hepatology*. 2021;75:797–813.
- Kennedy L, Carpino G, Owen T, Ceci L, Kundu D, Meadows V, et al. Secretin alleviates biliary and liver injury during late-stage primary biliary cholangitis via restoration of secretory processes. *J Hepatol*. 2022. <https://doi.org/10.1016/j.jhep.2022.07.034>.
- Wu N, Baiocchi L, Zhou T, Kennedy L, Ceci L, Meng F, et al. Functional role of the secretin/secretin receptor signaling during cholestatic liver injury. *Hepatology*. 2020;72(6):2219–27.
- Zhou T, Wu N, Meng F, Venter J, Giang TK, Francis H, et al. Knockout of secretin receptor reduces biliary damage and liver fibrosis in Mdr2^(-/-) mice by diminishing senescence of cholangiocytes. *Lab Invest*. 2018;98(11):1449–64.
- Wan Y, Meng F, Wu N, Zhou T, Venter J, Francis H, et al. Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells. *Hepatology*. 2017;66(2):528–41.
- Trussoni CE, O'Hara SP, LaRusso NF. Cellular senescence in the cholangiopathies a driver of immunopathology and a novel therapeutic target. *Semin Immunopathol*. 2022. <https://doi.org/10.1007/s00281-022-909-9>.
- Alpini G, Ulrich CD 2nd, Phillips JO, Pham LD, Miller LJ, LaRusso NF. Upregulation of secretin receptor gene expression in rat cholangiocytes after bile duct ligation. *Am J Physiol*. 1994;266(5 Pt 1):G922–8.
- Banales JM, Saez E, Uriz M, Sarvide S, Urribarri AD, Splinter P, et al. Up-regulation of microRNA 506 leads to decreased Cl/HCO₃⁻ anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. *Hepatology*. 2012;56(2):687–97.
- Alpini G, Glaser S, Robertson W, Rodgers RE, Phinizia JL, Lasater J, et al. Large but not small intrahepatic bile ducts are involved in secretin-regulated ductal bile secretion. *Am J Physiol*. 1997;272(5 Pt 1):G1064–74.
- Alpini G, Lenzi R, Sarkozi L, Tavoloni N. Biliary physiology in rats with bile ductular cell hyperplasia. Evidence for a secretory function of proliferated bile ductules. *J Clin Invest*. 1988;81(2):569–78.
- Alpini G, Roberts S, Kuntz SM, Ueno Y, Gubba S, Podila PV, et al. Morphological, molecular, and functional heterogeneity of cholangiocytes from normal rat liver. *Gastroenterology*. 1996;110(5):1636–43.
- Lleo A, Wang GQ, Gershwin ME, Hirschfeld GM. Primary biliary cholangitis. *Lancet*. 2020;396(10266):1915–26.
- Sasaki M, Sato Y, Nakanuma Y. An impaired biliary bicarbonate umbrella may be involved in dysregulated autophagy in primary biliary cholangitis. *Lab Invest*. 2018;98(6):745–54.
- Salas JT, Banales JM, Sarvide S, Recalde S, Ferrer A, Uriarte I, et al. Ae2a, b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. *Gastroenterology*. 2008;134(5):1482–93.
- van Niekerk J, Kersten R, Beuers U. Role of bile acids and the biliary HCO₃⁽⁻⁾ umbrella in the pathogenesis of primary biliary cholangitis. *Clin Liver Dis*. 2018;22(3):457–79.
- Chen L, Wu N, Kennedy L, Francis H, Ceci L, Zhou T, et al. Inhibition of secretin/secretin receptor axis ameliorates NAFLD phenotypes. *Hepatology*. 2021;74(4):1845–63.
- Prieto J, Garcia N, Marti-Climent JM, Penuelas I, Richter JA, Medina JF. Assessment of biliary bicarbonate secretion in humans by positron emission tomography. *Gastroenterology*. 1999;117(1):167–72.
- Wu N, Meng F, Zhou T, Venter J, Giang TK, Kyritsi K, et al. The secretin/secretin receptor axis modulates Ductular reaction and liver fibrosis through changes in transforming growth factor-beta1-mediated biliary senescence. *Am J Pathol*. 2018;188(10):2264–80.
- Bertola A, Mathews S, Ki SH, Wang H, Gao B. Mouse model of chronic and binge ethanol feeding (the NIAAA model). *Nat Protoc*. 2013;8(3):627–37.
- Carpino G, Del Ben M, Pastori D, Carnevale R, Baratta F, Overi D, et al. Increased liver localization of lipopolysaccharides in human and experimental NAFLD. *Hepatology*. 2020;72(2):470–85.
- Affo S, Nair A, Brundu F, Ravichandra A, Bhattacharjee S, Matsuda M, et al. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. *Cancer Cell*. 2021;39(6):866–82 e11.
- Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open source software for digital pathology image analysis. *Sci Rep*. 2017;7(1):16878.
- Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrilu C, et al. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA response score. *Lancet Gastroenterol Hepatol*. 2018;3(9):626–34.
- Zhou J, Huang N, Guo Y, Cui S, Ge C, He Q, et al. Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis. *Acta Pharm Sin B*. 2019;9(3):526–36.
- Kennedy L, Meadows V, Demieville J, Hargrove L, Virani S, Glaser S, et al. Biliary damage and liver fibrosis are ameliorated in a novel mouse model lacking l-histidine decarboxylase/histamine signaling. *Lab Invest*. 2020;100(6):837–48.
- Chen YY, Arndtz K, Webb G, Corrigan M, Akior S, Liaskou E, et al. Intrahepatic macrophage populations in the pathophysiology of primary sclerosing cholangitis. *JHEP Rep*. 2019;1(5):369–76.
- von Meijenfeldt FA, Stravitz RT, Zhang J, Adelmeijer J, Zen Y, Durkalski V, et al. Generation of neutrophil extracellular traps in patients with

- acute liver failure is associated with poor outcome. *Hepatology*. 2021;75:623–33.
41. Zhou X, Yang L, Fan X, Zhao X, Chang N, Yang L, et al. Neutrophil chemotaxis and NETosis in murine chronic liver injury via cannabinoid receptor 1/Galphai/o/ROS/p38 MAPK signaling pathway. *Cells*. 2020. <https://doi.org/10.3390/cells9020373>.
 42. Yang Z, Smalling RV, Huang Y, Jiang Y, Kusumanchi P, Bogaert W, et al. The role of SHP/REV-ERBalpha/CYP4A axis in the pathogenesis of alcohol-associated liver disease. *JCI Insight*. 2021. <https://doi.org/10.1172/jci.insight.140687>.
 43. Sekar R, Chow BK. Secretin receptor-knockout mice are resistant to high-fat diet-induced obesity and exhibit impaired intestinal lipid absorption. *FASEB J*. 2014;28(8):3494–505.
 44. Korompokis K, Verbeke K, Delcour JA. Structural factors governing starch digestion and glycemic responses and how they can be modified by enzymatic approaches: a review and a guide. *Compr Rev Food Sci Food Saf*. 2021;20(6):5965–91.
 45. Garcia C, Montuenga LM, Medina JF, Prieto J. In situ detection of AE2 anion-exchanger mRNA in the human liver. *Cell Tissue Res*. 1998;291(3):481–8.
 46. Kanno N, LeSage G, Glaser S, Alvaro D, Alpini G. Functional heterogeneity of the intrahepatic biliary epithelium. *Hepatology*. 2000;31(3):555–61.
 47. Ramirez T, Li YM, Yin S, Xu MJ, Feng D, Zhou Z, et al. Aging aggravates alcoholic liver injury and fibrosis in mice by downregulating sirtuin 1 expression. *J Hepatol*. 2017;66(3):601–9.
 48. Medina JF, Martinez A, Vazquez JJ, Prieto J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. *Hepatology*. 1997;25(1):12–7.
 49. Li Q, Dutta A, Kresge C, Bugde A, Feranchak AP. Bile acids stimulate cholangiocyte fluid secretion by activation of transmembrane member 16A Cl⁻ channels. *Hepatology*. 2018;68(1):187–99.
 50. LeSage G, Glaser S, Marucci L, Benedetti A, Phinizo JL, Rodgers R, et al. Acute carbon tetrachloride feeding induces damage of large but not small cholangiocytes from BDL rat liver. *Am J Physiol Gastrointest Liver Physiol*. 1999;276(5):G1289–301.
 51. Muir K, Hazim A, He Y, Peyressatre M, Kim DY, Song X, et al. Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma. *Cancer Res*. 2013;73(15):4722–31.
 52. Matsuzaka T, Kuba M, Koyasu S, Yamamoto Y, Motomura K, Arulmozhiraja S, et al. Hepatocyte ELOVL fatty acid Elongase 6 determines ceramide Acyl-Chain length and hepatic insulin sensitivity in Mice. *Hepatology*. 2020;71(5):1609–25.
 53. Kuba M, Matsuzaka T, Matsumori R, Saito R, Kaga N, Taka H, et al. Absence of Elov6 attenuates steatohepatitis but promotes gallstone formation in a lithogenic diet-fed Ldlr^{-/-} mouse model. *Sci Rep*. 2015;5:17604.
 54. Matsuzaka T, Atsumi A, Matsumori R, Nie T, Shinozaki H, Suzuki-Kemuriyama N, et al. Elov6 promotes nonalcoholic steatohepatitis. *Hepatology*. 2012;56(6):2199–208.
 55. Vogle A, Qian T, Zhu S, Burnett E, Fey H, Zhu Z, et al. Restricted immunological and cellular pathways are shared by murine models of chronic alcohol consumption. *Sci Rep*. 2020;10(1):2451.
 56. Alharshawi K, Aloman C. Murine models of alcohol consumption: imperfect but still potential source of novel biomarkers and therapeutic drug discovery for alcoholic liver disease. *J Cell Immunol*. 2021;3(3):177–81.
 57. Tripathy S, Lytle KA, Stevens RD, Bain JR, Newgard CB, Greenberg AS, et al. Fatty acid elongase-5 (Elov5) regulates hepatic triglyceride catabolism in obese C57BL/6j mice. *J Lipid Res*. 2014;55(7):1448–64.
 58. Gaudio E, Onori P, Pannarale L, Alvaro D. Hepatic microcirculation and peribiliary plexus in experimental biliary cirrhosis: a morphological study. *Gastroenterology*. 1996;111(4):1118–24.
 59. Gaudio E, Barbaro B, Alvaro D, Glaser S, Francis H, Ueno Y, et al. Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. *Gastroenterology*. 2006;130(4):1270–82.
 60. Govaere O, Cockell S, Van Haele M, Wouters J, Van Delm W, Van den Eynde K, et al. High-throughput sequencing identifies aetiology-dependent differences in ductular reaction in human chronic liver disease. *J Pathol*. 2019;248(1):66–76.
 61. Bocca C, Novo E, Miglietta A, Parola M. Angiogenesis and fibrogenesis in chronic liver diseases. *Cell Mol Gastroenterol Hepatol*. 2015;1(5):477–88.
 62. Lei L, Ei Mourabit H, Housset C, Cadoret A, Lemoinne S. Role of angiogenesis in the pathogenesis of NAFLD. *J Clin Med*. 2021. <https://doi.org/10.3390/jcm10071338>.
 63. Sayin SI, Wahlstrom A, Felin J, Jantti S, Marschall HU, Bamberg K, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. *Cell Metab*. 2013;17(2):225–35.
 64. Alpini G, Glaser S, Baiocchi L, Francis H, Xia X, LeSage G. Secretin activation of the apical Na⁺-dependent bile acid transporter is associated with cholehepatic shunting in rats. *Hepatology*. 2005;41(5):1037–45.
 65. Alpini G, Baiocchi L, Glaser S, Ueno Y, Marziani M, Francis H, et al. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha. *Hepatology*. 2002;35(5):1041–52.
 66. Lam IP, Lee LT, Choi HS, Alpini G, Chow BK. Bile acids inhibit duodenal secretin expression via orphan nuclear receptor small heterodimer partner (SHP). *Am J Physiol Gastrointest Liver Physiol*. 2009;297(1):G90–7.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

